I n the last decade, the FDA has annually approved approximately 20 new molecular entities (NME). Typically, a drug is tested in upward of 3,000 individuals prior to marketing, and in some cases, many more. As we have all learned in pharmacy school, the current drug development and safety monitoring program is cojoined during the preclinical phase of testing followed by three phases of clinical testing. In this model, drug safety is an important component of premarketing trials. Data regarding adverse events, drug interactions, and other safety issues are collected and assessed. Despite this attention to safety, these data are limited by sheer numbers and odds. Adverse events that occur less frequently or develop after chronic use may not be fully identified in premarketing clinical testing. Thus, it is not surprising that the safety profile of a drug changes once it is marketed and used in a broader and more diverse population than originally tested. In fact, once marketed, there is a 20% estimated probability that a drug will acquire a new black box warning or be withdrawn from the market over 25 years. 1 Thus, postmarketing surveillance remains an essential component in the drug-safety system as we currently know it.
Postmarketing surveillance of drugs varies greatly, ranging from spontaneous case reports of adverse events filed by health professionals or patients, and in some cases, carefully coordinated pharmacoepidemiologic studies performed by independent researchers or the pharmaceutical industry. It is not uncommon for the FDA to require or suggest that a manufacturer further examine safety issues in postmarketing study. However, this system is not without fault. According to a recent report, of the 1,231 postmarketing drug trials intended, 65% had not been started or were pending. 2 Recently, there has been much discussion about a change to the traditional drug development model. 3 The proposed model preserves the intent and scope of preclinical and premarketing phases of study (phases 1, 2, and 3) but offers a new conditional drug approval phase during which mandatory postmarketing studies are performed in an estimated 30,000 to 300,000 study participants. During this conditional drug-approval phase, premarketing issues regarding safety should be reasonably addressed and direct-to-consumer marketing should be restricted. Once these criteria have been met, the drug would receive full-drug approval, during which optional postmarketing trials may be conducted. In this newer model, the FDA would have a stronger role in the regulation of a drug once marketed. In addition, it has been suggested that a nongovernment, independent organization be developed to coordinate nonregulatory tasks (eg, study prescriber habits, etc).
One of the concerns with a safety system that emphasizes postmarketing evaluation is that drugs may be "rushed" through the premarketing phase at the expense of identifying important safety data. In the coming months, there should be much discussion regarding the benefits and potential hazards of altering the US drug-safety system. Continual assessment and evaluation of the current drugsafety system in the US is healthy. There is much room for improvement and increased involvement of all health care professionals in this process, particularly pharmacists.
